Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

BCX9930 para el tratamiento de C3G, IgAN y PMN (RENEW) (RENEW)

27 de octubre de 2026 actualizado por: BioCryst Pharmaceuticals

Un estudio abierto, de seguridad, tolerabilidad y prueba de concepto de la terapia oral con BCX9930 en sujetos con C3G, IgAN o PMN

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

2

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Barcelona, España
        • Investigative Site #1
      • Barcelona, España
        • Investigative Site #2
      • Madrid, España
        • Investigative Site #1
      • Madrid, España
        • Investigative Site #2
      • Poitiers, Francia
        • Investigative Site
      • Toulouse, Francia
        • Investigative Site
      • Bari, Italia
        • Investigative Site
      • Bergamo, Italia
        • Investigative Site
      • Brescia, Italia
        • Investigative Site
      • Turin, Italia
        • Investigative Site
      • Oxford, Reino Unido
        • Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Body weight ≥ 40 kilograms (kg)
  • Primary diagnosis of C3G, IgAN, or PMN confirmed by central pathology review
  • An estimated glomerular filtration rate (eGFR) ≥ 50 milliter per minute per 1.73 meter square (mL/min/1.73 m^2) (or ≥ 30 mL/min/1.73 m^2 after Data Monitoring Committee [DMC] recommendation)
  • Receiving treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1 Visit
  • Documentation of current vaccinations against Neisseria meningitidis and Streptococcus pneumoniae or willingness to start vaccination series

Exclusion Criteria:

  • Known congenital deficiency of C1s, C1r, C1q, C2, or C4
  • History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation
  • Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition
  • History of malignancy within 5 years prior to the screening visit
  • Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening
  • Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit
  • Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: C3G cohort

Approximately 14 eligible participants with C3G will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Experimental: IgAN cohort

Approximately 14 eligible participants with IgAN will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Experimental: PMN cohort

Approximately 14 eligible participants with PMN will be enrolled.

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percent Change From Baseline in 24-hour uPCR at Week 12
Periodo de tiempo: Baseline, Week 12

Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease.

Baseline, Week 12
Percent Change From Baseline in 24-hour uPCR at Week 24
Periodo de tiempo: Baseline, Week 24

Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease.

Baseline, Week 24

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cambio porcentual desde el valor inicial en la excreción de proteínas en orina de 24 horas
Periodo de tiempo: Línea de base, semanas 12, 24,
Línea de base, semanas 12, 24,
Change From Baseline in Estimated Glomerular Filtration Rate
Periodo de tiempo: Baseline, Weeks 12, 24

eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for participants ≥ 18 years old and by the bedside Schwartz formula for participants ≤ 18 years old. eGFR was reported in milliliter per minute per 1.73 per square meter (mL/min/1.73m^2).

Baseline, Weeks 12, 24
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)

An Adverse event (AE) was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Discontinued Due to a TEAE
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE)
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

A serious adverse event (SAE) was an adverse event/reaction that results in any of the following outcomes:

  • Death
  • Is life-threatening (participant was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe)
  • Requires participant hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization
  • Results in persistent or significant disability/incapacity (ie, there was a substantial disruption of a person's ability to carry out normal life functions)
  • Is a congenital anomaly/birth defect
From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 TEAE
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)

An AE was any untoward medical occurrence has no causal relationship with the study drug or with the clinical study itself. It was an unfavorable & unintended sign, symptom, syndrome, or illness that developed or worsened during clinical study.

TEAEs: AEs that started on or after first dose of treatment through 30 days after the last dose of study drug. All AEs were graded using the CTCAE Grades 1 through 5.

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL)

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL

Grade 4: Life-threatening consequences; urgent intervention indicated

Grade 5: Death

Participants with Grades 3 or 4 AEs were reported

From first dose up to safety follow-up period (Week 28)
Number of Participants Who Experienced a CTCAE Treatment-emergent Grade 3 or 4 Laboratory Abnormality
Periodo de tiempo: From first dose up to safety follow-up period (Week 28)

Treatment-emergent Laboratory Abnormality were defined as an event that started on or after the first dose of study treatment through 30 days after the last dose of study drug.

CTCAE Grades for laboratory abnormalities include:

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.

Grade 4: Life-threatening consequences; urgent intervention indicated.

Grade 5: Death

Participants with Grades 3 or 4 laboratory abnormality were reported.

From first dose up to safety follow-up period (Week 28)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Carla M Nester, MD, MSA, FASN, University of Iowa Stead Family Children's Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

18 de febrero de 2022

Finalización primaria (Actual)

23 de septiembre de 2022

Finalización del estudio (Actual)

23 de septiembre de 2022

Fechas de registro del estudio

Enviado por primera vez

26 de noviembre de 2021

Primero enviado que cumplió con los criterios de control de calidad

16 de diciembre de 2021

Publicado por primera vez (Actual)

17 de diciembre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir